Exclusive Sales Agreement for Innovative Histotripsy Platform in Japan
Exclusive Sales Agreement for the Histotripsy Platform
Gunze Medical Corporation, a subsidiary of Gunze Ltd., has entered into an exclusive sales agreement with HistoSonics, Inc. from the United States for the Histotripsy Platform in Japan. This strategic partnership grants Gunze Medical exclusive rights to sell this cutting-edge device within the Japanese market, marking a significant advancement in treating difficult liver tumors.
The Histotripsy Platform represents the world’s first non-invasive treatment method utilizing ultrasound-generated microbubbles. This innovative procedure, known as Histotripsy, focuses ultrasound energy to physically fragment tumors without the need for surgical incisions. By concentrating ultrasound waves into a
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.